- Shares of ZIOPHARM Oncology (ZIOP +10.7%) get a post-report tailwind.
- Investors like its collaboration with Intrexon (XON) for its RheoSwitch Therapeutic System, a method for modulating protein production in gene-based therapies.
- The company's lead product, Ad-RTS-IL-12, a novel gene expression platform for interleukin-12, is currently in P2 trials for the treatment of melanoma and breast cancer.
- Quick assets totaled $68.2M at years end and will be sufficient to fund operations into 2015's second quarter.
- Earnings release
ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12
at CNBC.com (Dec 7, 2013)